Reaction

Product Container Issue reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 8,318 reports · 75 co-occurring drugs

As of the last recalculation, Product Container Issue appears in 8,318 FAERS reports alongside 75 co-occurring drug terms. The strongest observed disproportionality signal is MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE (PRR 70.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Mometasone Furoate And Formoterol Fumarate Dihydrate	417	70.4	72.3
Lifitegrast	265	41.9	42.6
Mometasone Furoate	491	31.3	31.6
Carboxymethylcellulose Sodium	101	27.2	27.5
Cyclosporine	954	24.1	24.3
Travoprost	82	23.9	24.2
Brimonidine Tartrate	153	21.9	22.1
Timolol Maleate	72	18.3	18.5
Dorzolamide Hydrochloride And Timolol Maleate	56	17.8	18.0
Minoxidil	274	15.7	15.8
Latanoprost	266	13.6	13.7
Prednisolone Acetate	56	13.6	13.7
Brinzolamide	47	13.6	13.7
Bimatoprost	138	12.2	12.2
Timolol	55	11.5	11.5
Calcium, Magnesium, Potassium, And Sodium Oxybates	34	9.9	10.0
Clobetasol Propionate Ointment Usp, 0.05%	39	9.5	9.5
Clobetasol Propionate	36	8.7	8.8
Teduglutide	46	8.6	8.6
Icosapent Ethyl	27	8.0	8.0
Alteplase	40	6.7	6.7
Cannabidiol	50	5.4	5.4
Testosterone	48	5.2	5.2
Azelastine	31	4.3	4.3
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	14	4.3	4.3
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	43	3.5	3.5
Blinatumomab	14	3.4	3.4
Dapsone	14	3.3	3.3
Daspone	10	2.6	2.6
Dapsone Gel, 5%	10	2.6	2.6
Vibegron	8	2.5	2.5
Emicizumab	12	2.4	2.4
Testosterone Cypionate	8	2.2	2.2
Tretinoin	7	2.2	2.2
Cholestyramine	10	2.1	2.1
Moxifloxacin Hydrochloride	16	2.0	2.0
Tranexamic Acid	7	2.0	2.0
Clobazam	19	1.9	2.0
Risperidone	100	1.9	1.9
Infliximab-Dyyb	22	1.9	1.9
Biotin	23	1.8	1.8
Somatropin	53	1.8	1.8
Brivaracetam	6	1.7	1.7
Human Insulin	8	1.6	1.6
Onabotulinumtoxina	48	1.6	1.6
Phenobarbital	9	1.6	1.6
Epoprostenol	8	1.5	1.5
Tiotropium Bromide Inhalation Spray	6	1.3	1.3
Linaclotide	14	1.3	1.3
Triamcinolone Acetonide	16	1.3	1.3
Lanreotide Acetate	4	1.3	1.3
Armodafinil	10	1.2	1.2
Naproxen Sodium Tablet	25	1.2	1.2
Omalizumab	36	1.1	1.1
Ruxolitinib	29	1.0	1.0
Asfotase Alfa	4	1.0	1.0
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	1.0	1.0
Rimegepant Sulfate	5	1.0	1.0
Sodium Oxybate	26	1.0	1.0
Fentanyl Citrate	7	1.0	1.0
Ustekinumab	40	1.0	1.0
Budesonide, Glycopyrrolate, And Formoterol Fumarate	4	1.0	1.0
Daratumumab	14	0.9	0.9
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	3	0.8	0.8
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	6	0.8	0.8
Treprostinil	41	0.8	0.8
Paliperidone Palmitate	10	0.8	0.8
Suvorexant	4	0.8	0.8
Brexpiprazole	5	0.8	0.8
Guselkumab	10	0.7	0.7
Emtricitabine And Tenofovir Alafenamide	3	0.7	0.7
Glycerin, Lidocaine	3	0.5	0.5
Docosanol	3	0.5	0.5
Minoxidil Foam 5% (Womens)	6	0.5	0.5
Adapalene	3	0.0	0.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.